Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease

Free Radical Research

Volumn 45, Issue 1, 2011, Pages 59-72

  Butterfield, D Allan ^a,b   Reed, Tanea ^c   Sultana, Rukhsana ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University Richmond   (United States)

Author keywords

4 hydroxy 2 trans nonenal; Alzheimer's disease; early Alzheimer's disease; lipid peroxidation; mild cognitive impairment; protein nitration; proteomics

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; BRAIN PROTEIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 4; PEROXIREDOXIN 5; PEROXIREDOXIN 6;

ALZHEIMER DISEASE; CELL DEATH; CELL FUNCTION; CHOLINERGIC TRANSMISSION; CYTOSKELETON; DETOXIFICATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; ENZYME ACTIVITY; EXCITOTOXICITY; HUMAN; LIPID PEROXIDATION; MILD COGNITIVE IMPAIRMENT; NITRATION; NITROSATIVE STRESS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; STRESS;

ALDEHYDES; ALZHEIMER DISEASE; BRAIN; DISEASE PROGRESSION; HUMANS; NERVE TISSUE PROTEINS; OXIDATION-REDUCTION; OXIDATIVE STRESS; TYROSINE;

EID: 78650147789     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2010.520014     Document Type: Review

References (189)

1. Shen J, Kelleher RJ, 3rd. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 2007;104:403-409. (Pubitemid 46123039)
2. Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 2002;54:469-525.
3. Levy-Lahad E, Lahad A, Wijsman EM, Bird TD, Schellen-berg GD. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann Neurol 1995;38: 678-680.
4. de la Monte SM, Lu BX, Sohn YK, Etienne D, Kraft J, Ganju N, Wands JR. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging 2000;21:309-319. (Pubitemid 30387090)
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356. (Pubitemid 34790756)
6. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 2003; 278:42959-42965. (Pubitemid 37345908)
7. Lauderback CM, Hackett JM, Keller JN, Varadarajan S, Szweda L, Kindy M, Markesbery WR, Butterfield DA. Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer's disease. Biochemistry 2001; 40:2548-2554. (Pubitemid 32171729)
8. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147. (Pubitemid 27217017)
9. Butterfield DA, Koppal T, Subramaniam R, Yatin S. Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synap-tosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev Neurosci 1999; 10: 141-149. (Pubitemid 29392580)
10. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005;62:1160-1163; discussion 1167. (Pubitemid 41043744)
11. Nacmias B, Piccini C, Bagnoli S, Tedde A, Cellini E, Bracco L, Sorbi S. Brain-derived neurotrophic factor, apolipopro-tein E genetic variants and cognitive performance in Alzheimer's disease. Neurosci Lett 2004;367:379-383. (Pubitemid 39178617)
12. Almkvist O, Basun H, Backman L, Herlitz A, Lannfelt L, Small B, Viitanen M, Wahlund LO, Winblad B. Mild cognitive impairment-an early stage of Alzheimer's disease? J Neural Transm 1998;(Suppl 54):21-29. (Pubitemid 28539340)
13. Lafon-Cazal M, Culcasi M, Gaven F, Pietri S, Bockaert J. Nitric oxide, superoxide and peroxynitrite: putative mediators of NMDA-induced cell death in cerebellar granule cells. Neuropharmacology 1993;32:1259-1266. (Pubitemid 23322122)
14. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 2007;8:766-775. (Pubitemid 47462116)
15. Bergendi L, Benes L, Durackova Z, Ferencik M. Chemistry, physiology and pathology of free radicals. Life Sci 1999;65: 1865-1874. (Pubitemid 29506920)
16. Toader V, Xu X, Nicolescu A, Yu L, Bolton JL, Thatcher GR. Nitrosation, nitration, and autoxidation of the selective estrogen receptor modulator raloxifene by nitric oxide, peroxyni-trite, and reactive nitrogen/oxygen species. Chem Res Toxicol 2003;16:1264-1276. (Pubitemid 37315216)
17. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:1424-1437.
18. Broillet MC. S-nitrosylation of proteins. Cell Mol Life Sci 1999;55:1036-1042.
19. Gow AJ, Buerk DG, Ischiropoulos H. A novel reaction mechanism for the formation of S-nitrosothiol in vivo . J Biol Chem 1997;272:2841-2845. (Pubitemid 27053331)
20. Sampson JB, Rosen H, Beckman JS. Peroxynitrite-dependent tyrosine nitration catalyzed by superoxide dismutase, mye-loperoxidase, and horseradish peroxidase, Methods Enzymol 1996;269:210-218. (Pubitemid 26295710)
21. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield DA. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J Neurochem 1999;72: 310-317. (Pubitemid 29013906)
22. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy. J Neurosci 2002;22:3987-3993. (Pubitemid 37465707)
23. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman JS. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992;298:431-437.
24. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic Identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003;85:1394-1401. (Pubitemid 36702552)
25. Gow AJ, Duran D, Malcolm S, Ischiropoulos H. Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett 1996;385: 63-66. (Pubitemid 26153471)
26. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteom-ics approach. Neurobiol Dis 2006;22:76-87.
27. Koeck T, Fu X, Hazen SL, Crabb JW, Stuehr DJ, Aulak KS. Rapid and selective oxygen-regulated protein tyrosine deni-tration and nitration in mitochondria. J Biol Chem 2004;279: 27257-27262. (Pubitemid 38812564)
28. Aulak KS, Koeck T, Crabb JW, Stuehr DJ. Dynamics of protein nitration in cells and mitochondria. Am J Physiol Heart Circ Physiol 2004;286:30-38.
29. Bruijn LI, Beal MF, Becher MW, Schulz JB, Wong PC, Price DL, Cleveland DW. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1997;94:7606-7611.
30. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006;97:1676-1689. (Pubitemid 43873660)
31. Kunz A, Park L, Abe T, Gallo EF, Anrather J, Zhou P, Iade-cola C. Neurovascular protection by ischemic tolerance: role of nitric oxide and reactive oxygen species. J Neurosci 2007;27:7083-7093. (Pubitemid 47037566)
32. Malinski T. Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 2007;11:207-218. (Pubitemid 47018067)
33. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, Butterfield DA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 2006;8:1975-1986. (Pubitemid 46489625)
34. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-2657. (Pubitemid 27154998)
35. Williamson KS, Gabbita SP, Mou S, West M, Pye QN, Markesbery WR, Cooney RV, Grammas P, Reimann-Philipp U, Floyd RA, Hensley K. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide 2002;6:221-227. (Pubitemid 34848445)
36. Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Encinas JM, Serrano J, Bentura ML, Munoz P, Martinez-Murillo R, Rodrigo J. Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease. Neurobiol Dis 2004;15:287-305. (Pubitemid 38296760)
37. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998;18:8126-8132. (Pubitemid 28464991)
38. Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, LightFoot R, Bellmann C, Richter-Landsberg C, Lee VM, Trojanowski JQ. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 2003;163:1021-1031. (Pubitemid 37040138)
39. Zhang YJ, Xu YF, Liu YH, Yin J, Li HL, Wang Q, Wang JZ. Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. Faseb J 2006;20:1431-1442. (Pubitemid 44943851)
40. Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, Butterfield DA. Proteomic Identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med 2007;11:839-851. (Pubitemid 47313301)
41. Dalle-Donne I, Scaloni A, Butterfield DA. Redox proteom-ics. New York: Wiley; 2006.
42. Ekegren T, Hanrieder J, Aquilonius SM, Bergquist J. Focused proteomics in post-mortem human spinal cord. J Proteome Res 2006;5:2364-2371. (Pubitemid 44330829)
43. Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, Cini C, De Marco C, Butterfield DA. Pro-teomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics 2005;4:1849-1861. (Pubitemid 41830180)
44. De Iuliis A, Grigoletto J, Recchia A, Giusti P, Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin Chim Acta 2005;357:202-209. (Pubitemid 40894638)
45. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol Dis 2005;18:492-498. (Pubitemid 40332708)
46. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA. Proteomic Identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 2005;132: 313-324. (Pubitemid 40417906)
47. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic Identification of oxidatively modifi ed proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydro-lase L-1. Free Radic Biol Med 2002;33:562-571. (Pubitemid 34874977)
48. Poon HF, Farr SA, Thongboonkerd V, Lynn BC, Banks WA, Morley JE, Klein JB, Butterfield DA. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neu-rodegenerative disorders. Neurochem Int 2005;46: 159-168. (Pubitemid 41556623)
49. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA. Redox proteomics Identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 2006;27:1564-1576.
50. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 2006;22:76-87.
51. Butterfield DA, Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 2009; 111: 915-933.
52. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic Identification of oxidatively modifi ed proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase related protein II, a -enolase and heat shock cognate 71. J Neurochem 2002;82: 1524-1532.
53. Aksenova M, Butterfield DA, Zhang SX, Underwood M, Geddes J W. Increased protein oxidation and decreased crea-tine kinase BB expression and activity after spinal cord contusion injury. J Neurotrauma 2002;19:491-502. (Pubitemid 34412056)
54. Meier-Ruge W, Iwangoff P, Reichlmeier K. Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Ger-ontol Geriatr 1984;3:161-165. (Pubitemid 14030380)
55. Butterfield DA, Poon HF, St. Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR. Redox proteomics Identification of oxidatively modifi ed hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis 2006;22:223-232.
56. A Castegna VT, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic Identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003;85: 1394-1401. (Pubitemid 36702552)
57. Reed TT, Pierce WM, Jr, Turner DM, Markesbery WR, Butterfield DA. Proteomic Identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med 2009;13:2019-2029.
58. Eber SW, Pekrun A, Bardosi A, Gahr M, Krietsch WK, Kruger J, Matthei R, Schroter W. Triosephosphate isomerase defi -ciency: haemolytic anaemia, myopathy with altered mitochondria and mental retardation due to a new variant with accelerated enzyme catabolism and diminished specific activity. Eur J Pediatr 1991;150:761-766.
59. Zanella A, Mariani M, Colombo MB, Borgna-Pignatti C, De Stefano P, Morgese G, Sirchia G. Triosephosphate isomer-ase deficiency: 2 new cases. Scand J Haematol 1985;34: 417-424. (Pubitemid 15031717)
60. Kishi H, Mukai T, Hirono A, Fujii H, Miwa S, Hori K. Human aldolase A deficiency associated with a hemolytic anemia: thermolabile aldolase due to a single base mutation. Proc Natl Acad Sci USA 1987;84:8623-8627. (Pubitemid 18033464)
61. Hoyer S. Memory function and brain glucose metabolism. Pharmacopsychiatry 2003;36:62-67.
62. Butterfield DA, Sultana R. Redox proteomics Identification of oxidatively modifi ed brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimer's Dis 2007; 12: 61-72. (Pubitemid 47396301)
63. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A. Alterations in glucose metabolism induce hypothermia lead-ing to tau hyperphosphoylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci 2004;24:2401-2411. (Pubitemid 38327953)
64. Mancuso C, Barone E. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr Drug Metab 2009;10:579-594.
65. Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C, Butterfield DA. Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 2010;1333:72-81.
66. Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 1987;8:521-545. (Pubitemid 18006178)
67. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA. Redox proteomics Identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 2006;27:1564-1576. (Pubitemid 44344840)
68. Boyd-Kimall D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, Butterfield DA. Proteomic Identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 2005;1044: 206-215. (Pubitemid 40693453)
69. Lubec G, MN, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is down-regulated at the mRNA and dysregulated at the protein level. J Neural Transm 1999;(Suppl 57):161-177.
70. Kowaltowski AJ, Vercesi AE, Rhee SG, Netto LE. Catalases and thioredoxin peroxidase protect Saccharomyces cerevi-siae against Ca(2+)-induced mitochondrial membrane per-meabilization and cell death. FEBS Lett 2000;473: 177-182. (Pubitemid 30254286)
71. Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem 1997; 272:30615-30618. (Pubitemid 27527491)
72. Ichimiya S, Davis JG, O'Rourke DM, Katsumata M, Greene MI. Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. DNA Cell Biol 1997;16: 311-321. (Pubitemid 27148715)
73. Bae JY, Ahn SJ, Han W, Noh DY. Peroxiredoxin I and II inhibit H(2)O(2)-induced cell death in MCF-7 cell lines. J Cell Biochem 2007;101:1038-1045. (Pubitemid 47040883)
74. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004;4:3943-3952. (Pubitemid 39657469)
75. Kim SH, Fountoulakis M, Cairns N, Lubec G. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm 2001;(Suppl):223-235. (Pubitemid 38085085)
76. Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 2003;967:152-160. (Pubitemid 36324297)
77. Power JH, Asad S, Chataway TK, Chegini F, Manavis J, Temlett JA, Jensen PH, Blumbergs PC, Gai WP Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology. Acta Neuropathol 2008;115:611-622.
78. Bryk R, Griffi n P, Nathan C. Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature 2000;407:211-215.
79. Peshenko IV, Shichi H. Oxidation of active center cysteine of bovine 1-Cys peroxiredoxin to the cysteine sulfenic acid form by peroxide and peroxynitrite. Free Radic Biol Med 2001;31:292-303. (Pubitemid 32675334)
80. Lu K P. Phosphorylation-dependent prolyl isomerization: a novel cell cycle regulatory mechanism. Prog Cell Cycle Res 2000;4:83-96.
81. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl iso-merase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999;399:784-788. (Pubitemid 29293174)
82. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol Aging 2006;27:918-925.
83. Ralat LA, Manevich Y, Fisher AB, Colman RF. Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transerase pi with activity changes in both enzymes. Biochem 2006;45:360-372. (Pubitemid 43100403)
84. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128. (Pubitemid 121003917)
85. Fukuda M, Kanou F, Shimada N, Sawabe M, Saito Y, Murayama S, Hashimoto M, Maruyama N, Ishigami A. Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease. Biomed Res 2009;30:227-233.
86. Sayre LM, Sha W, Xu G, Kaur K, Nadkarni D, Subbana-gounder G, Salomon RG. Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal. Chem Res Toxicol 1996;9:1194-1201. (Pubitemid 26347974)
87. Nadkarni DV, Sayre LM. Structural Definaition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem Res Toxicol 1995;8:284-291.
88. Calingasan NY, Uchida K, Gibson GE. Protein-bound acro-lein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 1999;72:751-756. (Pubitemid 29055239)
89. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ, 2nd, Morrow JD, Montine TJ. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 2004;128:117-124. (Pubitemid 38167381)
90. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999;52:562-565. (Pubitemid 29075604)
91. Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 2009;1792: 643-650.
92. Perez-De La Cruz V, Elinos-Calderon D, Robledo-Arratia Y, Medina-Campos ON, Pedraza-Chaverri J, Ali SF, San-tamaria A. Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Hunt-ington's disease. Behav Brain Res 2009;199:210-217.
93. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 2010;4: 27-36.
94. Picklo MJ, Montine TJ, Amarnath V, Neely MD. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 2002;184:187-197. (Pubitemid 35428851)
95. Neely MD, Montine TJ. CSF lipoproteins and Alzheimer's disease. J Nutr Health Aging 2002;6:383-391. (Pubitemid 36024782)
96. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA. Redox proteomic Identification of 4-hydroxy-2-nonenal-modifi ed brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neuro-biol Dis 2008;30:107-120.
97. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial gluta-mate transporter, GLT-1, is oxidatively modifi ed by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem 2001;78:413-416. (Pubitemid 32664423)
98. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocam-pal cultures. Neurobiol Aging 2001;22:187-194. (Pubitemid 32162967)
99. McGrath LT, McGleenon BM, Brennan S, McColl D, Mc IS, Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malond-ialdehyde. QJM 2001;94:485-490. (Pubitemid 32894467)
100. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002; 32: 1050-1060. (Pubitemid 34603342)
101. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 2006;27:1094-1099. (Pubitemid 43850642)
102. Casado A, Encarnacion Lopez-Fernandez M, Concepcion Casado M, de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 2008;33:450-458. (Pubitemid 351230446)
103. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998;19:33-36. (Pubitemid 28167792)
104. Selley ML, Close DR, Stern SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002;23:383-388. (Pubitemid 34312021)
105. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 1997;18:457-461. (Pubitemid 27497140)
106. Reed TT, Pierce WM, Markesbery WR, Butterfield DA. Proteomic Identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res 2009;1274: 66-76.
107. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, Butterfield DA. Redox proteomics Identification of 4-hydroxynonenal-modifi ed brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 2009;3: 682-693.
108. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005;58:730-735. (Pubitemid 41552548)
109. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005;64:1152-1156.
110. Hellberg K, Grimsrud PA, Kruse AC, Banaszak LJ, Ohlen-dorf DH, Bernlohr DA. X-ray crystallographic analysis of adipocyte fatty acid binding protein (aP2) modifi ed with 4-hydroxy-2-nonenal. Protein Sci 2010;
111. Siems WG, Hapner SJ, van Kuijk FJ. 4-hydroxynonenal inhibits Na(+)-K(+)-ATPase. Free Radic Biol Med 1996;20:215-223.
112. Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, Butterfield DA. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 1997; 69:1161-1169. (Pubitemid 27364837)
113. Sultana R, Perluigi M, Butterfield DA. Redox proteomics Identification of oxidatively modifi ed proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J Chromatogr B Analyt Technol Biomed Life Sci 2006;833:3-11.
114. Castegna A, Lauderback CM, Mohmmad-Abdul H, Butterfield DA. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res 2004;1004:193-197. (Pubitemid 38368075)
115. Mattson MP. modification of ion homeostasis by lipid per-oxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci 1998;21:53-57. (Pubitemid 28078902)
116. Bader Lange ML, Cenini G, Piroddi M, Abdul HM, Sultana R, Galli F, Memo M, Butterfield DA. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis 2008;29:456-464.
117. Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 2002;22:1933-1941. (Pubitemid 34857007)
118. Kida K, Nishio T, Nagai K, Matsuda H, Nakagawa H. Gluconeogenesis in the kidney in vivo in fed rats. Circadian change and substrate specificity. J Biochem 1982;91:755-760. (Pubitemid 12116983)
119. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 2007;11:153-164.
120. Gomez A, Ferrer I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res 2009;87:1002-1013.
121. Barreiro E, Gea J, Di Falco M, Kriazhev L, James S, Hussain SN. Protein carbonyl formation in the diaphragm. Am J Respir Cell Mol Biol 2005;32:9-17. (Pubitemid 40053299)
122. Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox pro-teomics. Antioxid Redox Signal 2006;8:2021-2037. (Pubitemid 46499264)
123. Schapira AH. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedre-ich's ataxia. Biochim Biophys Acta 1999;1410:159-170. (Pubitemid 29078602)
124. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006;27:1372-1384. (Pubitemid 44279897)
125. Chen X, Stern D, Yan SD. Mitochondrial dysfunction and Alzheimer's disease. Curr Alzheimer Res 2006;3:515-520. (Pubitemid 46066427)
126. Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, Muller WE. Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp Gerontol 2006;41: 668-673. (Pubitemid 43866354)
127. Reix S, Mechawar N, Susin SA, Quirion R, Krantic S. Expression of cortical and hippocampal apoptosis-inducing factor (AIF) in aging and Alzheimer's disease. Neurobiol Aging 2007;28:351-356. (Pubitemid 46177383)
128. Kim SH, Vlkolinsky R, Cairns N, Lubec G. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol Life Sci 2000;57:1810-1816.
129. Muller WE, Eckert A, Kurz C, Eckert GP, Leuner K. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease-therapeutic aspects. Mol Neurobiol 2010;41:159-171.
130. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L. Mitochondrial dysfunction, oxidative stress and neurodegen-eration. J Alzheimers Dis 2006;10:59-73. (Pubitemid 44401367)
131. Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M. Mitochondria and neurodegeneration. Biosci Rep 2007;27:87-104. (Pubitemid 46940938)
132. Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, Smith MA. Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 2005;31:205-217. (Pubitemid 41271204)
133. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006;97:1634-1658. (Pubitemid 43873658)
134. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteom-ics. Eur J Pharmacol 2006; 545: 39-50. (Pubitemid 44215876)
135. Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, St Clair DK. Beta- amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 2006;168:1608-1618.
136. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 2005;57:695-703. (Pubitemid 40628858)
137. Op den Velde W, Stam FC. Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia. J Am Geriatr Soc 1976;24:12-16.
138. Battaini F, Pascale A, Lucchi L, Pasinetti GM, Govoni S. Protein kinase C anchoring Deficit in postmortem brains of Alzheimer's disease patients. Exp Neurol 1999;159:559-564. (Pubitemid 29485243)
139. Goldman JE. Immunocytochemical studies of actin localization in the central nervous system. J Neurosci 1983;3: 1952-1962. (Pubitemid 14233757)
140. Dalle-Donne I, Carini M, Vistoli G, Gamberoni L, Giustarini D, Colombo R, Maffei Facino R, Rossi R, Milzani A, Aldini G. Actin Cys374 as a nucleophilic target of alpha,beta-unsatu-rated aldehydes. Free Radic Biol Med 2007;42:583-598. (Pubitemid 46205143)
141. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 1994;174:67-72. (Pubitemid 24205235)
142. Gadoni E, Olivero A, Miglietta A, Bocca C, Gabriel L. Cytoskeletal modifications induced by 4-hydroxynonenal. Cytotechnology 1993;11(Suppl 1):62-64.
143. Neely MD, Boutte A, Milatovic D, Montine TJ. Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction. Brain Res 2005;1037:90-98. (Pubitemid 40362384)
144. Neely MD, Sidell KR, Graham DG, Montine TJ. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J Neurochem 1999;72:2323-2333. (Pubitemid 29242182)
145. Doorn JA, Maser E, Blum A., Claffey DJ, Petersen DR. Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry 2004;43:13106-13114. (Pubitemid 39366059)
146. Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 2007;47:293-22.
147. Balcz B, Kirchner L, Cairns N, Fountoulakis M, Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl 2001;61:193-201. (Pubitemid 38085082)
148. Lemieux N, Malfoy B, Forrest GL. Human carbonyl reduct-ase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells. Genomics 1993;15:169-172. (Pubitemid 23079585)
149. Forrest GL, Gonzalez B. Carbonyl reductase. Chem Biol Interact 2000;129:21-40. (Pubitemid 32061052)
150. Korenberg JR, Bradley C, Disteche CM. Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis. Am J Hum Genet 1992;50:294-302.
151. Petronis A. Alzheimer's disease and down syndrome: from meiosis to dementia. Exp Neurol 1999;158:403-413. (Pubitemid 29382830)
152. Yoshida Y, Yoshikawa A, Kinumi T, Ogawa Y, Saito Y, Ohara K, Yamamoto H, Imai Y, Niki E. Hydroxyoctadecadienoic acid and oxidatively modifi ed peroxiredoxins in the blood of Alzheimer's disease patients and their potential as biomark-ers. Neurobiol Aging 2009;30:174-185.
153. Ling M, Merante F, Chen HS, Duff C, Duncan AM, Robinson BH. The human mitochondrial elongation factor tu (EF-Tu) gene: cDNA sequence, genomic localization, genomic structure, and Identification of a pseudogene. Gene 1997;197:325-336. (Pubitemid 27399908)
154. Vayssiere JL, Cordeau-Lossouarn L, Larcher JC, Basseville M, Gros F, Croizat B. Participation of the mitochondrial genome in the differentiation of neuroblastoma cells. In Vitro Cell Dev Biol 1992;28A:763-772. (Pubitemid 23054050)
155. Pestova TV, Hellen CU. The structure and function of initiation factors in eukaryotic protein synthesis. Cell Mol Life Sci 2000;57:651-674. (Pubitemid 30311435)
156. Tome ME, Fiser SM, Payne CM, Gerner EW. Excess putrescine accumulation inhibits the formation of modifi ed eukaryotic initiation factor 5A (eIF-5A) and induces apop-tosis. Biochem J 1997;328:847-854. (Pubitemid 28005785)
157. Chang RC, Wong AK, Ng HK, Hugon J. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neurore-port 2002;13:2429-2432. (Pubitemid 36143538)
158. Ding Q, Markesbery WR, Cecarini V, Keller JN. Decreased RNA, and increased RNA oxidation, in Ribosomes from Early Alzheimer's Disease. Neurochem Res 2006;31:705-710. (Pubitemid 43886420)
159. Ferrer I. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease. Neuropathol Appl Neurobiol 2002;28:441-451. (Pubitemid 35425597)
160. Li X, An WL, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport 2004;15:2237-2240. (Pubitemid 39392247)
161. Sajdel-Sulkowska EM, Marotta CA. Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhib-itor complex. Science 1984;225:947-949. (Pubitemid 14064179)
162. Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. Ribos-ome dysfunction is an early event in Alzheimer's disease. J Neurosci 2005;25:9171-9175. (Pubitemid 41500825)
163. Calabrese V, Scapagnini G, Colombrita C, Ravagna A., Pennisi G, Giuffrida Stella AM, Galli F, Butterfield DA. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 2003;25:437-444. (Pubitemid 38041278)
164. Magrane J, Smith RC, Walsh K, Querfurth HW. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci 2004;24:1700-1706. (Pubitemid 38240967)
165. Keller JN, Hanni KB, Markesbery WR. Impaired proteas-ome function in Alzheimer's disease. J Neurochem 2000;75: 436-439. (Pubitemid 30418211)
166. Ojika K, Tsugu Y, Mitake S, Otsuka Y, Katada E. NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro . Brain Res Dev Brain Res 1998;106:173-180. (Pubitemid 28168483)
167. Jouvenceau A, Dutar P, Billard JM. Alteration of NMDA receptor-mediated synaptic responses in CA1 area of the aged rat hippocampus: contribution of GABAergic and cholinergic Deficits. Hippocampus 1998;8:627-637. (Pubitemid 29010190)
168. Davies P, Terry RD. Cortical somatostatin-like immunoreac-tivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. Neurobiol Aging 1981;2:9-14. (Pubitemid 11082130)
169. Davis BM, Mohs RC, Greenwald BS, Mathe AA, Johns CA, Horvath TB, Davis KL. Clinical studies of the cholinergic Deficit in Alzheimer's disease. I. Neurochemical and neu-roendocrine studies. J Am Geriatr Soc 1985;33:741-748. (Pubitemid 16183969)
170. Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, Dick DJ, Candy JM, Edwardson JA, Fairbairn A. Cholinergic receptors in cognitive disorders. Can J Neurol Sci 1986;13: 521-527. (Pubitemid 17212714)
171. Rossor MN, Iversen LL, Johnson AJ, Mountjoy CQ, Roth M. Cholinergic Deficit in frontal cerebral cortex in Alzheimer's disease is age dependent. Lancet 1981;2:1422.
172. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholin-ergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147. (Pubitemid 29103513)
173. George AJ, Holsinger RM, McLean CA, Tan SS, Scott HS, Cardamone T, Cappai R, Masters CL, Li QX. Decreased phos-phatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging 2006;27:614-623. (Pubitemid 43290530)
174. Bader Lange ML, St Clair D, Markesbery WR, Studzinski CM, Murphy MP, Butterfield DA. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) X PS1-(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol Dis 2010; 38:104-115.
175. Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M. A novel gene family defi ned by human dihydro-pyrimidinase and three related proteins with differential tissue distribution. Gene 1996;180:157-163. (Pubitemid 26417923)
176. Kato Y, Hamajima N, Inagaki H, Okamura N, Koji T, Sasaki M, Nonaka M. Post-meiotic expression of the mouse dihy-dropyrimidinase-related protein 3 (DRP-3) gene during spermiogenesis. Mol Reprod Dev 1998;51:105-111. (Pubitemid 28372964)
177. Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 1995;376: 509-514.
178. Wang FS, Wolenski JS, Cheney RE, Mooseker MS, Jay DG. Function of myosin-V in filopodial extension of neuronal growth cones. Science 1996;273:660-663. (Pubitemid 26262122)
179. Arimura N, Inagaki N, Chihara K, Menager C, Nakamura N, Amano M, Iwamatsu A, Goshima Y, Kaibuchi K. Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem 2000;275:23973-23980. (Pubitemid 30624686)
180. Fukata Y, Itoh TJ, Kimura T, Menager C, Nishimura T, Shiromizu T, Watanabe H, Inagaki N, Iwamatsu A, Hotani H, Kaibuchi K. CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol 2002;4: 583-591.
181. Gu Y, Ihara Y. Evidence that collapsin response mediator protein-2 is involved in the dynamics of microtubules. J Biol Chem 2000;275:17917-17920. (Pubitemid 30414732)
182. Yoshida H, Watanabe A, Ihara Y. Collapsin response mediator protein-2 is associated with neurofi brillary tangles in Alzheimer's disease J Biol Chem 1998;273:9761-9768. (Pubitemid 28183069)
183. Baloyannis SJ, Costa V, Mauroudis I, Psaroulis D, Manolides SL, Manolides LS. Dendritic and spinal pathology in the acoustic cortex in Alzheimer's disease: morphological and mor-phometric estimation by Golgi technique and electron microscopy. Acta Otolaryngol 2007;127:351-354. (Pubitemid 46572867)
184. Butterfield DA, Hensley K, Cole P, Subramaniam R Aksenov M, Aksenova M, Bummer PM, Haley BE, Carney JM. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem 1997; 68: 2451-2457. (Pubitemid 27218166)
185. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Butterfield DA. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65:2146-2156.
186. Carney JM, Carney AM. Role of protein oxidation in aging and in age-associated neurodegenerative diseases. Life Sci 1994;55:2097-2103. (Pubitemid 24372599)
187. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, Konishi J. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med 1994;35:1-6. (Pubitemid 24018423)
188. Ogawa M, Fukuyama H, Ouchi Y, Yamauchi H, Kimura J. Altered energy metabolism in Alzheimer's disease. J Neurol Sci 1996;139:78-82. (Pubitemid 26246283)
189. Gotz ME, Kunig G, Riederer P, Youdim MB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994;63:37-122. (Pubitemid 24250150)